genO-BRGSF-HISマウスにおける腫瘍微小環境（TME）のヒト免疫細胞構成は、腫瘍細胞株由来異種移植片のサブタイプおよび腫瘍負荷に依存する

背景

The relevance of preclinical models has vastly improved with mice bearing a human immune system, especially in the context of immunotherapy. genO-BRGSF (BALB/c Rag2^-/-, IL2Rγ^-/-, SIRPα^NOD and Flt3^-/-) is a highly immunodeficient mouse featuring reduced murine myeloid cells. genO-BRGSF mice reconstituted with human cord blood CD34+ cells (genO-BRGSF-HIS) develop functional lymphoid and myeloid compartments. This engraftment is stable for over a year⁽¹⁾ and mice do not develop GvHD. Additionally, t h e myeloid compartment can be transiently boosted with exogenous human Flt3L injections. In contrast to other models that overexpress human cytokines to develop human myeloid cells, Flt3L-treated genO-BRGSF-HIS mice do not show side effects. genO-BRGSF-HIS mice are permissive to mouse and human cancer cell line engraftment, hence representing a valuable preclinical model to study cancer development and evaluate novel therapeutics.

‍